Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.

摘要: 529Background: TAS-102 is an oral nucleoside antitumor agent, comprising trifluridine (FTD) and tipiracil. FTD incorporated into DNA after phosphorylation by thymidine kinase 1 (TK1). This study aimed to investigate the association between TK1 expression efficacy in refractory metastatic colorectal cancer (mCRC) patients (pts). Methods: Data from two randomized phase 2 3 studies of mCRC pts standard therapies were analyzed for treatment outcomes relation expression. Expression was measured using immunohistochemistry, staining classified according intensity scored 0, 1+, 2+, or 3+. Occupancy rates areas 2+ 3+ tumor cells calculated 5% intervals, divided groups (high low TK1) at each cut-off point. Results: evaluated 329 pts. Baseline characteristics comparable TK1-refined intention-to-treat populations. Pts with high wh...